Activated protein C and septic shock: A propensity-matched cohort study

Critical Care Medicine

Volumn 40, Issue 11, 2012, Pages 2974-2981

  Rimmer, Emily ^a,b   Kumar, Anand ^a,c   Doucette, Steve ^d   Marshall, John ^e   Dial, Sandra ^f   Gurka, David ^g   Phillip Dellinger, R ^c   Sharma, Satendra ^a   Penner, Charles ^h   Kramer, Andreas ^h   Wood, Kenneth ⁱ   Ronald, John ^j   Kumar, Aseem ^k   Turgeon, Alexis F ^l,m   Houston, Donald S ^a,b   Zarychanski, Ryan ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CancerCare Manitoba ^*  (Canada)

^c Department of Anesthesiology   (United States)

^d Capital District Health Authority   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

^h Brandon Regional Health Authority   (Canada)

ⁱ University of Wisconsin Health   (United States)

^j Nanaimo Regional Hospital   (Canada)

^k LAURENTIAN UNIVERSITY   (Canada)

^l LAVAL UNIVERSITY   (Canada)

^m UNIVERSITÉ LAVAL   (Canada)

more..

Author keywords

activated protein c; anticoagulants; critical illness; sepsis; septic shock

Indexed keywords

ANTIINFECTIVE AGENT; DROTRECOGIN;

ADULT; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPTIC SHOCK; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFECTIVE AGENTS; CANADA; COHORT STUDIES; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROPENSITY SCORE; PROTEIN C; RECOMBINANT PROTEINS; SAUDI ARABIA; SHOCK, SEPTIC; UNITED STATES;

EID: 84868206959     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31825fd6d9     Document Type: Article

References (30)

1. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150
2. Matthay MA: Severe sepsis-A new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med 2001; 344:759-762
3. Food and Drug Administration: FDA Clinical Review Drotrecogin Alfa (Activated) [Recombinant Human Activated Protein C (rhAPC)] Xigris™, 2011. Available at: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/UCM113438.pdf. Accessed May 5, 2011
4. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
5. Angus DC, Laterre PF, Helterbrand J, et al; PROWESS Investigators: The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 2004; 32: 2199-2206
6. Abraham E, Laterre PF, Garg R, et al; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341
7. Nadel S, Goldstein B, Williams MD, et al; REsearching severe Sepsis and Organ dysfunction in children: A gLobal perspective (RESOLVE) Study Group: Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomised controlled trial. Lancet 2007; 369:836-843
8. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (Activated) in adults with septic shock. N Engl J Med 2012; 366:2055-2064
9. Eli-Lilly and Company: Lilly announces withdrawal of Xigris(R) following recent clinical trial results. Available at: https://investor.lilly. com/releasedetail.cfm?ReleaseID=617602. Accessed October 25, 2011
10. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596
11. Kumar A, Zarychanski R, Light B, et al; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group: Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensitymatched analysis. Crit Care Med 2010; 38: 1773-1785
12. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655
13. Suissa S: Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 2007; 16:241-249
14. Zarychanski R, Doucette S, Fergusson D, et al: Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med 2008; 36:2973-2979
15. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
16. Eli-Lilly and Company: Xigris (drotrecogin alfa (activated)) Prescribing Information. Available at: http://pi.lilly.com/us/xigris.pdf. Accessed March 20, 2011
17. Schoenfeld DA, Bernard GR; ARDS Network: Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med 2002; 30:1772-1777
18. Austin PC: A critical appraisal of propensityscore matching in the medical literature between 1996 and 2003. Stat Med 2008; 27:2037-2049
19. Glynn RJ, Schneeweiss S, St?mer T: Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98:253-259
20. Luellen JK, Shadish WR, Clark MH: Propensity scores: An introduction and experimental test. Eval Rev 2005; 29:530-558
21. Brookhart MA, Schneeweiss S, Rothman KJ, et al: Variable selection for propensity score models. Am J Epidemiol 2006; 163:1149-1156
22. Parsons LS: SUGI 26. Reducing Bias in a Porpensity Score Matched-Pair Sample Using Greedy Matching Techniques: The SAS Institute, 2001. Available at: http://www2.sas.com/proceedings/sugi26/p214-26.pdf. Available at: October 30, 2010
23. Parsons LS: SUGI 29. Performing a 1:N Case-Control Match on Propensity Score. The SAS Institute, 2004. Available at: http://www2. sas.com/proceedings/ sugi29/165-29.pdf. Accessed January 17, 2012.
24. Taylor JM: Choosing the number of controls in a matched case-control study, some sample size, power and efficiency considerations. Stat Med 1986; 5:29-36
25. Lindenauer PK, Rothberg MB, Nathanson BH, et al: Activated protein C and hospital mortality in septic shock: A propensitymatched analysis. Crit Care Med 2010; 38:1101-1107
26. Sadaka F, O'Brien J, Migneron M, et al: Activated protein C in septic shock: A propensitymatched analysis. Crit Care 2011; 15:R89
27. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
28. Dellinger RP, Levy MM, Carlet JM, et al; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
29. Zarychanski R, Turgeon AF, Hebert PC: The use of anticoagulants in severe sepsis and septic shock: A national survery of critical care physicians. Crit Care Med 2009; 37(Suppl 12):A427
30. Kanji S, Perreault MM, Chant C, et al: Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: A Canadian multicenter observational study. Intensive Care Med 2007; 33:517-523